Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Registro dei risultati prospettici della fibrosi polmonare idiopatica e della malattia polmonare interstiziale (IPF/ILD-PRO)

9 novembre 2026 aggiornato da: Duke University

Registro degli esiti prospettici della fibrosi polmonare idiopatica (IPF-PRO) e della malattia polmonare interstiziale fibrosante cronica con esiti prospettici del fenotipo progressivo (IPF-PRO/ILD-PRO)

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Panoramica dello studio

Descrizione dettagliata

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Tipo di studio

Osservativo

Iscrizione (Stimato)

3000

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • Reclutamento
        • University of Alabama - Birmingham
        • Investigatore principale:
          • Tejaswini Kulkarni, MD
        • Contatto:
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85721
        • Reclutamento
        • University of Arizona
        • Investigatore principale:
          • Sally A Suliman, MD
        • Contatto:
    • California
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • University of Southern California
        • Contatto:
        • Investigatore principale:
          • Toby Maher, MD
      • Los Angeles, California, Stati Uniti, 90024
        • Reclutamento
        • University of California - Los Angeles
        • Investigatore principale:
          • John Belperio, MD
        • Contatto:
      • Stanford, California, Stati Uniti, 94305
        • Reclutamento
        • Stanford University
        • Investigatore principale:
          • Rishi Raj, MD
        • Contatto:
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • University of Colorado
        • Investigatore principale:
          • Joyce Lee, MD
        • Contatto:
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06520
        • Reclutamento
        • Yale University
        • Investigatore principale:
          • Mridu Gulati, MD
        • Contatto:
    • Florida
      • Gainesville, Florida, Stati Uniti, 32610-3175
        • Reclutamento
        • University of Florida
        • Contatto:
        • Investigatore principale:
          • Diana Gomez Manjarres, MD
      • Tampa, Florida, Stati Uniti, 33606
        • Reclutamento
        • University of South Florida
        • Investigatore principale:
          • Jose D Herazo-Maya, MD
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University
        • Contatto:
        • Investigatore principale:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, Stati Uniti, 30106
        • Reclutamento
        • Piedmont Healthcare
        • Investigatore principale:
          • Amy Case, MD
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago
        • Investigatore principale:
          • Mary Strek, MD
        • Contatto:
      • Evanston, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern University
        • Contatto:
        • Investigatore principale:
          • Bradford Bemiss, MD
      • Maywood, Illinois, Stati Uniti, 60153
        • Reclutamento
        • Loyola University Health System
        • Investigatore principale:
          • Daniel Dilling, MD
        • Contatto:
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Terminato
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky
        • Investigatore principale:
          • Girish Nair, MD
        • Contatto:
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70112
        • Reclutamento
        • Tulane University
        • Investigatore principale:
          • Joe Lasky, MD
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Attivo, non reclutante
        • University of Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Reclutamento
        • Henry Ford Health
        • Contatto:
        • Investigatore principale:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55455
        • Reclutamento
        • University of Minnesota
        • Contatto:
        • Investigatore principale:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, Stati Uniti, 39216
        • Reclutamento
        • University of Mississippi Medical Center
        • Investigatore principale:
          • Kimberly Dobbs, MD
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University
        • Investigatore principale:
          • Tonya Russell, MD
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Weill Medical College of Cornell University
        • Investigatore principale:
          • Kerri Aronson, MD
        • Contatto:
      • New York, New York, Stati Uniti, 10016
        • Attivo, non reclutante
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27514
        • Reclutamento
        • UNC Chapel Hill
        • Investigatore principale:
          • Jason Lobo, MD
        • Contatto:
      • Durham, North Carolina, Stati Uniti, 27705
        • Reclutamento
        • Duke University
        • Investigatore principale:
          • Lake Morrison, MD
        • Contatto:
      • Greensboro, North Carolina, Stati Uniti, 27403
        • Reclutamento
        • Pulmonix LLC
        • Investigatore principale:
          • Murali Ramaswamy, MD
        • Contatto:
      • Wilmington, North Carolina, Stati Uniti, 28401
        • Terminato
        • PMG Research
      • Winston-Salem, North Carolina, Stati Uniti, 27157
        • Reclutamento
        • Wake Forest Baptist Health
        • Contatto:
        • Investigatore principale:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45267
        • Attivo, non reclutante
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • Cleveland Clinic
        • Investigatore principale:
          • Brian Southern, MD
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • The Ohio State University
        • Contatto:
        • Investigatore principale:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • University of Oklahoma
        • Investigatore principale:
          • Jad Kebbe, MD
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97220
        • Reclutamento
        • Oregon Clinic
        • Investigatore principale:
          • David Hotchkin, MD
        • Contatto:
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Reclutamento
        • Penn State College of Medicine - Hershey
        • Investigatore principale:
          • Rebecca Bascom, MD
        • Contatto:
      • Philadelphia, Pennsylvania, Stati Uniti, 19140
        • Reclutamento
        • Temple University
        • Investigatore principale:
          • Rachel Criner, MD
        • Contatto:
      • Philadelphia, Pennsylvania, Stati Uniti, 19144
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Reclutamento
        • Medical University of South Carolina
        • Investigatore principale:
          • Timothy Whelan, MD
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University
        • Contatto:
        • Investigatore principale:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, Stati Uniti, 75235
        • Reclutamento
        • University of Texas Southwestern
        • Investigatore principale:
          • John Fitzgerald, MD
        • Contatto:
      • Dallas, Texas, Stati Uniti, 75246
        • Reclutamento
        • Baylor University Medical Center at Dallas
        • Investigatore principale:
          • Yolanda Mageto, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Baylor College of Medicine
        • Investigatore principale:
          • Ivan Rosas, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Houston Methodist Lung Center
        • Investigatore principale:
          • Zeenat Safdar, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas Health Science Center At Houston
        • Investigatore principale:
          • Rodeo Abrencillo, MD
        • Contatto:
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84108
        • Reclutamento
        • University of Utah
        • Contatto:
        • Investigatore principale:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, Stati Uniti, 84111
        • Reclutamento
        • Intermountain Health
        • Contatto:
        • Investigatore principale:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, Stati Uniti, 05446
        • Attivo, non reclutante
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Attivo, non reclutante
        • University from Virginia
      • Falls Church, Virginia, Stati Uniti, 22042-3307
        • Reclutamento
        • Inova Health Care Services
        • Contatto:
        • Investigatore principale:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Attivo, non reclutante
        • The Medical College of Wisconsin

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

21 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Descrizione

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Data on management practices compared to existing guidelines.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 giugno 2014

Completamento primario (Stimato)

1 gennaio 2028

Completamento dello studio (Stimato)

1 gennaio 2031

Date di iscrizione allo studio

Primo inviato

31 luglio 2013

Primo inviato che soddisfa i criteri di controllo qualità

1 agosto 2013

Primo Inserito (Stimato)

5 agosto 2013

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi